Mobile

An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal o...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-000744-28

An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal or over 70 years of age

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that a second dose of ZOSTAVAX elicits higher varicella-zostervirus (VZV) antibody titers than first dose of ZOSTAVAX whether given a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at weeks 4 post-vaccination

Critère d'inclusion

  • Herpes zoster and post-herpetic neuralgia

Liens